The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.

Disclosed is a method for reducing the appearance of a wrinkle on skin comprising topically applying to said wrinkle a composition that includes an effective amount of ornithine, retinol, Commiphora mukul resin or an extract thereof, and hyaluronic acid, wherein topical application of the composition reduces the appearance of said wrinkle within 120 seconds after application of the composition, and wherein topical application of said composition stimulates adipogenesis in said skin.

Methods of treating aging related skin changes and of increasing skin thickness with topical administration of N-acyldipeptide derivatives are described. Compositions comprising N-acyldipeptide derivatives, are therapeutically effective for increasing skin thickness, and for treating extrinsic and intrinsic aging and aging related skin changes, such as fine lines, wrinkles, photoaging, hyperpigmentation, laxity, age spots, lentigines, mottled skin, and cellulite.

Methods of treating aging related skin changes and of increasing skin thickness with topical administration of N-acyldipeptide derivatives are described. Compositions comprising N-acyldipeptide derivatives, are therapeutically effective for increasing skin thickness, and for treating extrinsic and intrinsic aging and aging related skin changes, such as fine lines, wrinkles, photoaging, hyperpigmentation, laxity, age spots, lentigines, mottled skin, and cellulite.

To provide a novel agent for ameliorating a skin symptom such as pigmented macules or ephelides, a novel hair growth agent, and a novel slimming agent. The agent for ameliorating a skin symptom, the hair growth agent, or the slimming agent contains a dopamine agonist as an active ingredient, in which the skin symptom is selected from pigmented macules, periorbital dark circles, darkish skin, black darkish skin, moles, ephelides, birth marks, and seborrheic keratosis.

A method for simultaneously moisturizing and/or blurring the appearance of skin defects, or reducing pore size, or treating skin with a multi-benefit composition.

A method for simultaneously moisturizing and/or blurring the appearance of skin defects, or reducing pore size, or treating skin with a multi-benefit composition.

A cosmetic or pharmaceutical method for the treatment and/or care of the skin and/or hair which includes administering to the skin and/or hair an effective amount of at least one peptide of general formula (I):

R.sub.1-AA.sub.1-AA.sub.2-AA.sub.3-R.sub.2 (I) where AA.sub.1 and AA.sub.2 are independently selected from -Tyr- and -Phe- and AA.sub.3 is selected from -Nle- and -Met-, its stereoisomers, mixtures thereof and/or cosmetically or pharmaceutically acceptable salts thereof, in the treatment and/or care of conditions, disorders and/or diseases of the skin and/or hair by stimulating cyclic adenosine monophosphate synthesis (cAMP).

A cosmetic or pharmaceutical method for the treatment and/or care of the skin and/or hair which includes administering to the skin and/or hair an effective amount of at least one peptide of general formula (I):

R.sub.1-AA.sub.1-AA.sub.2-AA.sub.3-R.sub.2 (I) where AA.sub.1 and AA.sub.2 are independently selected from -Tyr- and -Phe- and AA.sub.3 is selected from -Nle- and -Met-, its stereoisomers, mixtures thereof and/or cosmetically or pharmaceutically acceptable salts thereof, in the treatment and/or care of conditions, disorders and/or diseases of the skin and/or hair by stimulating cyclic adenosine monophosphate synthesis (cAMP).

Liposomal and/or nano-liposomal encapsulated HSP90a, HPf polypeptide (115 aa) and novel polypeptides HPf C1 (101 aa) and HPfC2 (87 aa), as well as methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include an HSP90a, HPf-polypeptide, HPf C1 or HPfC2 polypeptide are presented. Transformed cell lines and expression vectors capable of expressing the chimeric fusion proteins, are provided. Methods for producing large amounts of recombinant HSP90a, HPf polypeptide, HPf C1 or HPfC2 polypeptide, using expression vectors and transformed cell lines, are described. Topical and other delivery form preparations and methods for using the preparations, including methods for improving skin conditions (atopic dermatitis, wrinkles, skin elasticity, dark spots (over pigmentation), overall skin rejuvenation, skin ageing) for therapeutic and cosmeceutical uses are presented. Liposomal preparations and methods for using them for enhancing wound healing and methods for suppressing subcutaneous fat cell differentiation and reducing subcutaneous fat formation are disclosed.